![]() DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. ![]() DSM's purpose is to create brighter lives for all. corn ethanol industry for 2005–2019: implications for greenhouse gas emission reductions ĭSM Bio-based Products & Services is part of Royal DSM, a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. We are delighted to add DSM's technology to our platform to deliver improvements in fermentation yield with reduced byproduct formation." Casper Vroemen, Vice President Global Research and Development, Health & Biosciences division, IFF stated, "Continued development of the best commercial embodiments of our yeast technology has been a key focus of our Grain Processing technology platform. By increasing yields, speeding up fermentation, reducing energy and chemical consumption, IFF's XCELIS® Ethanol Solutions platform is helping ethanol producers meet the challenges of today's renewable energy market.ĭr. High yield yeasts and other advancements in the ethanol industry have enabled US producers to increase ethanol yields by 6.5%, reduce energy inputs by 24% while delivering ever-greater quantities of low carbon biofuels and animal feed*. As we approach this July's International Fuel Ethanol Workshop & Expo, the team looks forward to supporting the industry with the broadest portfolio of yeast and enzyme products and the technology to drive superior operational and financial performance." IFF will launch eBoost® GTX along with other new yeast products during 2021 including SYNERXIA® RUBY and SYNERXIA® SAPPHIRE.Ĭindy McCracken, Vice President Grain Processing Business, Health & Biosciences division, IFF stated, "We are ready to serve the needs of new and current customers of both IFF and DSM. It delivers low glycerol, high ethanol yield and up to 70% glucoamylase replacement. By combining the strengths of the companies' patented and proprietary technologies, IFF's XCELIS® Ethanol Solutions platform will deliver new yeasts with unparalleled yield, robustness and enzyme expression.ĭSM newest yeast, eBoost® GTX, is currently undergoing US plant trials. In addition, IFF's R&D team will collaborate with DSM scientists to accelerate IFF's on-going development of high-performance yeast products. Under the terms of this agreement, DSM's eBoost® product line will immediately become part of IFF's XCELIS® Ethanol Solutions platform and will be offered and supported by IFF's experienced global commercial team. Under IFF's agreement with DSM to offer advanced yeasts for first generation ethanol, DSM's eBoost® product line will immediately become part of IFF's XCELIS® Ethanol Solutions platform and will be offered and supported by IFF's experienced global commercial team.ĬEDAR RAPIDS, Iowa, J/PRNewswire-PRWeb/ - IFF's Health & Biosciences division, a world leader in sustainable biotechnology solutions, announced today that they have entered into an agreement to offer advanced yeasts for first generation ethanol production developed by DSM Bio-based Products & Services. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |